Objective: To investigate the safety and efficacy for weight loss of simmondsin, a dietary supplement extracted from the seed of the jojoba plant (Simmondsia chinensis). Animals: Sprague-Dawley male rats were fed various levels of simmondsin for 8 weeks (lean rats) or 16 weeks (high fat-induced obese rats). Measurements: Food intake, body weight and composition, histopathology, hematology parameters. Results: Simmondsin produced a clear dose-response effect on food intake and body weight. No remarkable histopathologic changes were noted in the liver, kidney and spleen. One lean animal, in the 0.5% group, had approximately a 20% depression in red bone marrow cells. Significant effects on hematology parameters were seen almost exclusively in groups consuming simmondsin at the highest level (0.5%) and these effects appeared to be reversed by removing simmondsin from the diet. Conclusion: Simmondsin at both the 0.15% level and the 0.25% level significantly reduced food intake and body weight without apparent negative effects. At dose levels much higher than therapeutic levels, there seemed to be reversible effects on circulating red and white blood cells. Future studies should determine long-term effects of lower doses on blood cell parameters.
Introduction
Simmondsin, a 2-cyanomethylene)-3 hydroxy 4,5 dimethoxy cyclohexyl b-D-glucoside, is a dietary supplement that is extracted from the seed of jojoba plant (Simmondsia chinensis). Jojoba is native to the Sonora desert of the American South West and Mexico. Oil is extracted from the seed for commercial use in cosmetics and shampoos. The remaining meal is approximately 30% protein and has a markedly suppressive effect on food intake in a variety of species. Several early studies suggested that simmondsin is toxic, as rats fed jojoba meal at 5-10% of rations for 94 days decreased food intake to such an extent that the rats became emaciated and died. 1 More recent studies suggested that simmondsin extracted from jojoba could inhibit food intake without direct toxicity. In 1980, Verbiscar et al. 2 reported that five mice died when fed simmondsin at 750 mg/kg for 14 days and three surviving mice showed signs of hepatotoxicity and possible intestinal hemorrhage. Intraperitoneal administration of the same dose, however, did not decrease body weight of rats nor were there any other drug-induced effects. Subsequent pair-feeding studies, using more moderate levels of simmondsin, suggested that its effects are primarily because of decreased voluntary food consumption. Rats fed 250 mg/kg for 5 days showed no toxicological influences on biochemical parameters of the liver, pancreas and kidneys and no pathological changes were found in kidney, liver, pancreas, stomach, intestine, testis and seminal vesicle. 3 Teratological studies found lower birth weights of jojobatreated rat dams compared with a pair-fed group, to be because of lower body weight gain during gestation; offspring showed no other abnormalities and subsequently reproduced normally. 4 Simmondsin may reduce food intake by increasing satiety [5] [6] [7] via an indirect interaction with the peripheral CCK A system. Cokelaere et al. 8 found that simmondsin's effect on satiety was abolished by administration of a CCK A receptor-antagonist (devazepide), which had previously been shown to inhibit the anorexic effect of exogenous CCK in both rats and mice. 9, 10 Vagotomy, in rats, also reduced the effects of both exogenously administered simmondsin and CCK, 8 suggesting that simmondsin's augmentation of satiety, like that of CCK, is mediated, in part, by the vagus nerve. A recent study by York et al., 11 however, renewed concerns about simmondsin's toxicity. In this study, simmondsin had negative effects on hematopoiesis in rats even at doses that did not affect food intake or body weight. The authors concluded that simmondsin is 'toxic with profound effects on the hematopoietic system.' The purpose of the present two studies was to determine, in rats, the safety and efficacy for weight loss of the form of simmondsin currently available for clinical use. The first study replicated and extended (to 8-weeks) the 4-week doseranging study of York et al. 11 in lean, male, rats, purchased from the same vendor at the same age, and fed simmilar levels of simmondsin in a similar diet (commercial rat chow). The second study, modeling the clinical weight loss treatment of obese individuals, assessed simmondsin for weight loss in rats that had been made obese by feeding them a high fat diet. This longer term study (16 weeks) also assessed reversibility of simmondsin's effects. These studies are relevant clinically, as products containing simmondsin are currently marketed in the US as dietary supplements that are advertised to provide a 'natural appetite suppressant' (ProJoba Slim, ProJoba, Int., Laguna Hill, CA, USA) or to 'regulate appetite' (LipoDize, Eclipse 2000, Scranton, PA, USA).
Materials and methods

Animals and maintenance
Seventy male, Sprague-Dawley rats weighing 375725 g were purchased from Harlan Labs, (Indianapolis, IN, USA). On arrival, the rats were individually housed in hanging, suspended stainless steel cages. All rats were provided with commercial powdered rat chow (Lab Diet, PMI Nutrition International, St Louis, MO, USA) diet during an initial observation period of 1 week, after which the animals were allocated to either experiment 1, in which groups received simmondsin (S) in the diets according to the protocol described in the Experimental Design section, or experiment 2, in which rats were fed a high fat diet for 2 months to induce obesity prior to being allocated to experimental groups. Food and water were allowed ad libitum to all animals throughout the study. Food intake, including spillage, and body weight were measured 3 times/week. Tail blood was collected at intervals during the experiment and trunk blood at completion of each experiment when rats were killed by CO 2 overdose. The St Luke's-Roosevelt Hospital Center Animal Care Facility cared for the animals in accordance with a protocol approved by the Institutional Animal Care and Use Committee.
Experimental design Experiment 1. After the initial week of observation, the 40 rats in Experiment 1 were weight-matched into five groups (N ¼ 8/group) provided with commercial ground rat chow containing the following concentrations (by weight) of S ('Non-Apetit' Pharmachem Laboratories, Inc., Nutley, NJ, USA): 0.00%, 0.015%, 0.050%, 0.150%, 0.500%. Blood collected at 4 and 8 weeks was analyzed (vet screen) by commercial laboratory. Rats were killed at 8 weeks, blood clotting was timed and gross necropsy performed that included the examination of external surfaces of the body and all viscera. Tissues and organs were removed, weighed and samples fixed in 10% formalin. Remaining tissues were returned to the carcasses, which were later subjected to total chemical analysis for fat, nitrogen and water by methods previously described. 12 The fixed tissues were subsequently embedded in paraffin. Paraffin blocks were cut at 5 mm and stained with hematoxylin and eosin. A veterinary pathologist (AJH), blinded to treatment designation, carried out the histopathological examination of the stained tissues: liver, kidney, spleen and bone marrow from the sternum.
Experiment 2. Following 1 week of observation, all rats in experiment 2 were provided an ad libitum high-fat diet (HFD) for 8 weeks. The HFD was prepared using a commercial mixer with Crisco (Procter & Gamble, Cincinnati, OH, USA) vegetable shortening, casein and powdered chow to produce a diet of the following macronutrient proportions of energy: 45% fat, 20% protein, 35% carbohydrate. After 8 weeks of HFD, the rats were weight-matched into four groups of eight rats per group. One group (Control) continued to consume the HFD with no S. The other groups were provided simmondsin in the HFD diet at either 0.25% by weight (one group), or at 0.5% (two groups). After 8 weeks, tail blood was collected from all of the animals and one of the 0.5% S groups was then switched back to the HFD Control diet. After an additional 8 weeks, all rats were killed and blood and tissues collected and analyzed as described above.
Statistics
Data are presented as means7standard deviation (s.d.) in tables and means7standard error (s.e.) in figures. All statistical analyses were performed using SPSS 11.0 for Windows (SPSS, Inc., Chicago, IL, USA). Body weight and food intake were analyzed by GLM Repeated Measures. Body composition data was analyzed by one-way ANOVA followed by LSD post hoc tests. Blood values for Experiment 1 were analyzed by GLM with repeated measures followed by LSD post hoc tests and for Experiment 2 by one-way ANOVA followed by LSD post hoc tests. The level of significance was determined at Po0.05.
Results
Experiment 1: Lean animals Body weight, food intake and body composition. Simmondsin produced a clear dose-response effect on body weight
Simmondsin for weight loss CN Boozer and AJ Herron ( Figure 1 ). Weights of rats in the two lowest simmondsin groups were not statistically different from the control group. The 0.15% S dose had a small but persistent effect to reduce body weight gain, while the highest dose (0.50%) produced an rapid loss of about 6% of body weight, with maintenance of this reduced weight throughout the remainder of the experiment. Eight-week body weight changes (78.6713 and 73.6714 g) of rats fed the two lowest simmondsin doses (0.015 and 0.05%) were not different from the control group (74719 g), while weight changes of the groups fed 0.15 and 0.50% (51.2713 and À15.8713 g) were significantly (Po0.05 and Po0.01) different from those of each of the other three groups. The effect of S, above the 0.05% level, on food intake was marked, immediate and dose dependent (Figure 2 ). Mean total food intakes per group over the 8-week study were not different between the control group and the two lowest dose simmondsin groups: 1201765, 1236732 and 1223743 g. The total intake of the 0.15 group (1169745 g) was less than that of the 0.05 group (Po0.05) and greater than the 0.5 group (Po0.001), while the intake of the 0.5 group (940728 g) was significantly (Po0.001) less than any of the other four groups.
Chemical body composition analysis was performed on the control group and the groups consuming the two highest levels of S. Groups consuming simmondsin had significantly (Po0.05) smaller carcass weights (384720 and 319712 vs 406725 g), with groups consuming the highest levels of simmondsin having significantly (Po0.05) less fat (2974 g), protein (6673 g) and water (21377 g) than the control group (3576, 887 4 and 268715 g, respectively) ( Table 1) . When expressed as percent of carcass weight, however, simmondsin groups were different (Po0.05) from controls only for percent protein.
Liver weights were not significantly different (P40.05) between groups whether expressed as absolute weight or as percent of carcass weight ( Table 2 ). Mean kidney weights (average of both right and left kidneys) did not differ between groups, with the exception of the group fed 0.15% S, which was significantly (Po0.05) heavier than controls (1.6970.12 vs 1.5270.12 g). Expressed as percent of carcass weight, mean kidney weights of the highest dose simmond- Simmondsin for weight loss CN Boozer and AJ Herron sin groups in both studies were increased relative to their respective control groups.
Histopathology. There were no remarkable histopathologic effects in the liver, kidney or spleen. One animal, in the 0.5% group, had approximately a 20% depression in red bone marrow cells. The cells affected included erythroid precursors, granulocytic cells and megakaryocytes.
Hemotology parameters. Simmondsin had significant effects on hemotology parameters, only in the group consuming simmondsin at the highest level (0.5%), (Table 3a) . Compared with all other groups, the group fed simmondsin at the 0.5% level had lower levels of white blood cells, red blood cells and lymphocytes. Blood clotting time did not differ among groups (data not shown).
Experiment 2: Diet-induced obese animals Body weight, food intake, body composition. Compared with rats in the Control group, those fed simmondsin at the 0.25% and the 0.5% levels had body weight gains that were reduced in proportion to the simmondsin in their diets (Figure 3 ). Body weights of the group switched from 0.5% S to the control diet (0.5/0.0% S), increased rapidly and continued to increase throughout the remainder of the study, but did not catch up with the control group by the end of the experiment. The 16-week changes in body weight were significantly (Po0.05) different between each of the treatment groups and all other groups (Control: 120724; 0.25% S: 29742; 0.5% S: À20714; 0.5/0.0% S: 75716 g).
Suppression of food intake was directly related to the level of simmondsin in the diet (Figure 4) , with the Control group eating more food (Po0.05) than any group consuming S. For Simmondsin for weight loss CN Boozer and AJ Herron the first week following the change from 0.5% S to a control diet, rats increased food intake to more than any other group (Po0.001). For the remaining weeks, this group did not differ in food intake from the Control group, but ate more than either of the two simmondsin groups (Po0.05). Total food intake over the study was significantly different (Po0.05) for each group compared with all other groups (Control: 2110789; 0.25% S: 1886748; 0.5% S: 1766768; 0.5/0.0% S: 1983765 g). Reductions in body composition compartments were proportional to the amount of simmondsin in the diet ( Table 1 ). The control group had significantly (Po0.05) more fat, protein and water than either the 0.25 or the 0.5% S group. As a percent of carcass weight, however, the effects of simmondsin were limited to fat and water as there were no significant differences between any of the groups for protein.
Compared with the control group, the 0.5/0.0% S group had lower (Po0.05) carcass weights but similar (P40.05) proportions of protein, fat and water.
Absolute liver and kidney (mean) weights did not differ among treatment groups ( Table 2) . As percentage of carcass weight, however, both kidney and liver were increased relative to controls in the treatment groups receiving simmondsin for 16 weeks, but not in the 0.5/0.0% S group.
Histopathology. All tissues sampled were found to be within normal limits.
Hemotology parameters. Simmondsin had statistically significant effects on hemotology parameters, in the group consuming simmondsin at the highest level (0.5%). These included reductions in hemoglobin, white blood cells, red blood cells, MCV and lymphocytes at 8 weeks and hemoglobin, hematocrit, red blood cells, MCV and MCH at 16 weeks (Table 3b ). The only statistically significant differences between groups were higher MCV levels at 16 weeks in the 0.25% S group and significantly lower levels in the 0.5/0.0% S group.
Discussion
At a sufficiently high dose, most weight loss agents produce unacceptable side effects. The practical question is whether an acceptable dose can be identified that promotes weight loss without untoward side effects. Results from these relatively short-term studies suggest that, at least in rats, it may be possible to identify such a dose for the simmondsin product that was studied, although further research is needed to determine whether trends for reduction in blood Simmondsin for weight loss CN Boozer and AJ Herron cell counts seen in this study might become significant over longer time scales.
In both lean and diet-induced obese adult rats, simmondsin produced immediate, dose-related suppression of food intake that resulted in proportionally reduced body weights. Relative to controls, lean rats fed simmondsin had slightly lower percent body protein, while obese rats fed simmondsin had reduced percent body fat. Blood-clotting time was not affected by simmondsin. Gross examination of the animals at the conclusion of the experiments showed no abnormalities, and histopathological examination of liver, kidney, spleen and bone marrow showed abnormalities in only one animal. That animal, given the highest dose of simmondsin in Experiment 1, had reduced red bone marrow cells. Analysis of blood samples revealed significant reductions in red and white blood cells, as well as other components that were almost exclusively in the groups consuming the highest level of simmondsin. The absence of these changes, except for MCV reduction, in the group fed 0.5% S for 8 weeks followed by 0% S for another 8 weeks, suggests that simmondsin's effects on these hemotology parameters is reversible. The trend for reductions of blood cell counts in rats fed lower doses, while not statistically significant, point to the need for longer term studies to determine whether they might continue to decrease and eventually become significant.
The study by York et al. 11 found that simmondsin consumption was related to animal death, failure of blood to clot, and marked depression of red marrow activity and lymphoid follicles in the spleen and presence of occasional protein casts in the renal tubules. York et al. described 'watery blood in body cavities'. Their chronic study of 0.5% simmondsin was terminated at 52 days due to the high death rate (5/10 rats), whereas no rats in our studies died, even in the group consuming the highest dose (0.5%) of simmondsin for 16 weeks. The most likely explanation for the dramatic differences between our results and those of York et al.
11 would seem to be differences in the composition of the simmondsin, since the rats for the two studies were purchased at the same age, gender and body weight from the same vendor and were fed the same doses of simmondsin in similar chow diets. York et al. found no components other than demethyl-simmondsin (at o1%) when they examined the simmondsin used in their studies by HPLC, TLC and mass-spectrometry. Nonetheless, it is difficult to avoid the conclusion that some 'toxic' component from jojoba meal must have been excluded to greater extent by the extraction procedure (unpublished, Avoca Inc., Merry Hill, NC, USA) used for the simmondsin in the current study than by the procedure 13 used to prepare simmondsin for the York study. It will be important to compare these two materials. Simmondsin, in our study, at both the 0.15% level (Experiment 1) and the 0.25% level (Experiment 2), significantly reduced food intake and body weight without significant negative effects. However, at dose levels much higher than those therapeutic levels, there seemed to be deleterious effects on circulating red and white blood cells, although these were mostly reversible. Additional therapeutic dose level studies of longer duration are warranted to determine longer term effects on bone marrow and blood cell production, in rats as well as in other species. Design and interpretation of such studies will be also be advanced by comparative analyses of the products of various simmondsin extraction processes.
